Printer Friendly

CARDIOPULMONICS REPORTS FOCUSED DEVELOPMENT EFFORTS, CASH CONSERVATION MEASURES IN CONTINUING ANTICIPATION OF A LENGTHY PMA REVIEW

 SALT LAKE CITY, Aug. 13 /PRNewswire/ -- CardioPulmonics(R) Inc. (NASDAQ-NMS: CRDS) today reported the following:
 CardioPulmonics submitted a pre-market approval (PMA) application for its IVOX(R) device (Intravascular Oxygenator) to the U.S. Food and Drug Administration (FDA) in May 1993. To date, the FDA continues to review the application regarding the acceptability of the clinical data and a filing decision. In continuing efforts to conserve cash in anticipation of a lengthy PMA review by the FDA, CardioPulmonics today took steps to reduce its payroll by 30 percent along with related expenses.
 CardioPulmonics will focus its internal development efforts on improvements to the IVOX gas exchange capability and ease of use and on the manufacturing processes for its thromboresistant TRC(R) coatings. In addition, the company continues to pursue licensing opportunities for its TRC coating technology. The company reaffirmed that it will seek more immediate revenue generating opportunities by means of acquiring complementary products, technologies or businesses.
 CardioPulmonics Inc. manufactures the IVOX(R) device under an IDE (Investigational Device Exemption) from the FDA.
 -0- 8/13/93
 /CONTACT: William S. Barth, CFO of CardioPulmonics, 801-350-3600/
 (CRDS)


CO: CardioPulmonics Inc. ST: California IN: MTC SU:

EH-MF -- LA036 -- 2694 08/13/93 16:40 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 13, 1993
Words:203
Previous Article:K-SWISS SHOES: THE PAPAL CHOICE FOR POPE JOHN PAUL II'S THIRD VISIT TO THE UNITED STATES
Next Article:UNOCAL AND STATE OF ALASKA SETTLE TAX DISPUTE
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters